search
Back to results

Risk Factors and Progression of Keratoconus (FRPK)

Primary Purpose

Keratoconus

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
cross-linking surgery or intra corneal ring
abstention
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Keratoconus

Eligibility Criteria

10 Years - 40 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Participants with clinical keratoconus (Rabinowitz criteria with topographic slit lamp abnormalities and visual impairment), preclinical or crude keratoconus (abnormal or suspicious topography with normal slit lamp examination and normal visual acuity, visual acuity) Followed by the ophthalmology services of the CHU Montpellier, CHU Bordeaux or CHU Toulouse For adult Participants: collection of written informed consent, after a period of reflection period For minors: informed consent signed by at least one of the 2 parents or legal representatives legal representatives, and assent of the child after a period of reflection Affiliation to the French social security system or beneficiary of such a system Exclusion Criteria: Person under legal supervision, guardianship or curator History of corneal implant on both eyes Planned relocation before the end of the first stage of treatment (abstention, cross-linking, intra-corneal ring depending on the participant)

Sites / Locations

  • CHU Gui de Chauliac - Service d'OphtamologieRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Abstention

Intervention (cross-linking surgery or intra corneal ring)

Arm Description

After keratoconus diagnosis the patient won't be assigned to intervention

After keratoconus diagnosis the patient was assigned to cross linking surgery or intra corneal ring surgery

Outcomes

Primary Outcome Measures

Keratoconus clinical progression (Keratometry map)
Modelisation of refraction measurements in diopters, by corneal elevation topography (Orbscan and Pentacam), giving an additional indicator of the corneal deformity. High values of diopter correspond to positive bulges of the cornea. A topographic axial map will be acquired to monitor minimal and maximal keratometry. These measurements will be taken at baseline and compared for reference of progression at each visit for each eye. Keratoconus definition according to Rabinowitz (Rabinowitz YS, 1989) criteria: Corneal asymmetry greater than 1.5 diopters (D), between the upper and lower part of the cornea, on the median vertical axis. Central corneal power (Kmax) > 47.2 D, measured at the top of the cone. Asymmetry of central keratometry > 1D between the two eyes
Keratoconus clinical progression (Pachymetric map)
Thickness of the cornea will be assessed in microns (µm) at several locations and will be presented as a map by corneal elevation topography (Orbscan and Pentacam). The pachymetric map will be acquired at baseline and compared for reference of progression at each visit for each eye. The higher and lower thickness points will be notified for the anterior and posterior parts of the eye.
Keratoconus clinical progression (Visual acuity test)
Visual acuity test with and without correction: decimal and Parinaud scales secondarily translated in LogMar.
Keratoconus clinical progression (Biomicroscopic examination of the cornea)
A biomicroscopic examination of the cornea in search of signs that may modify the therapeutic indications i.e : Fleischer rings (iron deposits in the lower part of the bulge, due to the stagnation of tears), visible corneal nerves, corneal opacities (due to scar tissue)
ABCD grading of keratoconus
Grading of the keratoconus, according to the ABCD classification : A: keratometry of the anterior surface of the cornea (Anterior radius of curvature (ARC)), in the area of 3 mm centered by the thinnest point. B: keratometry of the posterior surface of the cornea (Back or posterior radius of curvature PRC), in the 3mm area centered by the thinnest point. C: thinnest point of the Cornea, i.e. minimum pachymetry. D: Distance best corrected vision: visual acuity with the best correction, measured in 10° or in the Parinaud scale.
Keratoconus histological progression - Confocal microscopy (tissue thickness)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Tissue thickness in microns (µm)
Keratoconus histological progression - Confocal microscopy (Cellular organization)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Cell organization and morphology. Image acquisition. Colonization by inflammatory cells (yes/no), increased nucleo/cytoplasmic ratio (yes/no), hyperreflectivity of the nuclei (yes/no). Nerve density of the basal plexuses of normal appearance (yes/no), straight with branches (yes/no), normal hyperreflectivity (yes/no)
Keratoconus histological progression - Confocal microscopy (Cellular density)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Cellular density (number). Image acquisition. - Cell count in the different layers, corneal nerve count from the basal plexus to the corneal apex
Keratoconus histological progression - Confocal microscopy (Light scattering)
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Light scattering in vivo, measurement of corneal deformity. Diopter.
Risk factors - Questionnaire
Presence of atopy/allergy Eye rubbing Family medical history Ethnicity Smoking habits Dry eye syndrome
Tears proteomics
For 36 participants from Montpellier. Composition and evolution of tears determined by proteomic analysis

Secondary Outcome Measures

ABCD class worsening between consultations
At baseline and during follow-up
Keratoconus histological evolution
Comparison of confocal microscopy results from primary outcomes through time.
Proteomic profile evolution
Difference between the composition of tears from healthy participants and from keratoconus patients from baseline to short term follow up.

Full Information

First Posted
December 18, 2022
Last Updated
August 1, 2023
Sponsor
University Hospital, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT05676580
Brief Title
Risk Factors and Progression of Keratoconus
Acronym
FRPK
Official Title
Risk Factors and Progression of Keratoconus
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 5, 2023 (Actual)
Primary Completion Date
June 5, 2025 (Anticipated)
Study Completion Date
May 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary objective : Description of keratoconus at baseline and during progression in 200 participants followed by the ophthalmology departments of CHU Montpellier, CHU Bordeaux and CHU Toulouse during a 2-year period. Clinical outcome, histology of the cornea and tears proteomics will be assessed in 4 groups at different points in time: At 6 months in participants with no intervention (risk reduction instructions: not to rub their eyes) At 6 months in participants with no intervention that didn't comply with the risk reduction instructions At 1 month in participants assigned to cross-linking surgery At 1 month in participants assigned to intra corneal ring surgery If both eyes are affected, both will be evaluated with their own visit agenda. Visits for no surgery participants will be set at 6 months, 12 months and 24 months in the absence of intervention (apart from the behavioral risk reduction). Visits for surgery participants will be set at D7, 1 month, 6 months, 12 months and 24 months after the procedure: cross-linking or placement of the intra corneal ring. Secondary objective : Description of the association between clinical outcomes, histological progression of the cornea and tears proteomics in time, 2 years period. Comparison of tears proteomics in 36 participants with keratoconus followed at CHU of Montpellier and healthy participants at baseline .
Detailed Description
This trial is a prospective cohort study of 200 participants with keratoconus followed by the ophthalmology departments of CHU Montpellier, CHU Bordeaux and CHU Toulouse during a 2-year period. If both eyes are affected, each will be evaluated considering their own visit agenda. Histological and proteomic evaluations will be performed in 36 participants's eyes whose initial management is abstention of surgery (12 participants), cross-linking (12 participants) or intra corneal ring (12 participants). The target population consist of participants with clinical keratoconus (topographic Rabinowitz criteria with slit lamp abnormalities and visual impairment), preclinical or crude keratoconus (abnormal or suspicious topography with normal slit lamp examination and normal visual acuity). They will be aged between 10 and 40 years included. The follow-up will be taken care off by the ophthalmology departments of the Montpellier University Hospital, Bordeaux University Hospital or Toulouse University Hospital Collection of written informed consent, after a period of reflection, will be necessary for adult participants. For minors: informed consent will have to be signed by at least one of the 2 parents or legal guardians, and approval from the child will be asked after a period of reflection. All participants will have to be affiliated to the French social security system or beneficiary of such a system. Description of the study course: No therapeutic intervention outside of routine care will be performed. Depending on the therapeutic orientation, the follow-up is carried out as follows: Visits at 6 months, 12 months and 24 months in the absence of intervention (apart from the behavioral risk reduction management). Visits at day 7, 1 month, 6 months, 12 months and 24 months after the procedure: cross-linking or placement of the intra corneal ring. In this study, participants will be followed for a maximum of 2.5 years. In addition to the description of keratoconus progression, we will take a tear sample using the Schirmer test to create a biobank. This tears collection will be performed in 36 participants followed at the Montpellier University Hospital, at inclusion and at short-term follow-up visit (6 months if abstention, 1 month if surgery). Judging criteria: Paraclinical examination of the participants Ophthalmological paraclinical data Confocal microscopy examination ABCD classification of keratoconus Composition and evolution of tears determined by proteomic analysis Survey on risk factors: allergies, atopy, ocular friction, family history, ethnic origin, smoking, dry eye syndrome, low pachymetry Prevalence of risk factors: a survey will measure the prevalence of risk factors for keratoconus: Presence of atopy/allergy Eye rubs Family history Ethnic origin Tobacco use Dry eye syndrome (survey + clinical examination) Low pachymetry This self-survey will be completed at the inclusion visit and at the last follow-up visit (M24). The time to complete this questionnaire is approximately 10 minutes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keratoconus

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Abstention
Arm Type
Other
Arm Description
After keratoconus diagnosis the patient won't be assigned to intervention
Arm Title
Intervention (cross-linking surgery or intra corneal ring)
Arm Type
Other
Arm Description
After keratoconus diagnosis the patient was assigned to cross linking surgery or intra corneal ring surgery
Intervention Type
Procedure
Intervention Name(s)
cross-linking surgery or intra corneal ring
Intervention Description
After keratoconus diagnosis the patient was assigned to surgery
Intervention Type
Other
Intervention Name(s)
abstention
Intervention Description
No surgery
Primary Outcome Measure Information:
Title
Keratoconus clinical progression (Keratometry map)
Description
Modelisation of refraction measurements in diopters, by corneal elevation topography (Orbscan and Pentacam), giving an additional indicator of the corneal deformity. High values of diopter correspond to positive bulges of the cornea. A topographic axial map will be acquired to monitor minimal and maximal keratometry. These measurements will be taken at baseline and compared for reference of progression at each visit for each eye. Keratoconus definition according to Rabinowitz (Rabinowitz YS, 1989) criteria: Corneal asymmetry greater than 1.5 diopters (D), between the upper and lower part of the cornea, on the median vertical axis. Central corneal power (Kmax) > 47.2 D, measured at the top of the cone. Asymmetry of central keratometry > 1D between the two eyes
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus clinical progression (Pachymetric map)
Description
Thickness of the cornea will be assessed in microns (µm) at several locations and will be presented as a map by corneal elevation topography (Orbscan and Pentacam). The pachymetric map will be acquired at baseline and compared for reference of progression at each visit for each eye. The higher and lower thickness points will be notified for the anterior and posterior parts of the eye.
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus clinical progression (Visual acuity test)
Description
Visual acuity test with and without correction: decimal and Parinaud scales secondarily translated in LogMar.
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus clinical progression (Biomicroscopic examination of the cornea)
Description
A biomicroscopic examination of the cornea in search of signs that may modify the therapeutic indications i.e : Fleischer rings (iron deposits in the lower part of the bulge, due to the stagnation of tears), visible corneal nerves, corneal opacities (due to scar tissue)
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
ABCD grading of keratoconus
Description
Grading of the keratoconus, according to the ABCD classification : A: keratometry of the anterior surface of the cornea (Anterior radius of curvature (ARC)), in the area of 3 mm centered by the thinnest point. B: keratometry of the posterior surface of the cornea (Back or posterior radius of curvature PRC), in the 3mm area centered by the thinnest point. C: thinnest point of the Cornea, i.e. minimum pachymetry. D: Distance best corrected vision: visual acuity with the best correction, measured in 10° or in the Parinaud scale.
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus histological progression - Confocal microscopy (tissue thickness)
Description
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Tissue thickness in microns (µm)
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus histological progression - Confocal microscopy (Cellular organization)
Description
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Cell organization and morphology. Image acquisition. Colonization by inflammatory cells (yes/no), increased nucleo/cytoplasmic ratio (yes/no), hyperreflectivity of the nuclei (yes/no). Nerve density of the basal plexuses of normal appearance (yes/no), straight with branches (yes/no), normal hyperreflectivity (yes/no)
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus histological progression - Confocal microscopy (Cellular density)
Description
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Cellular density (number). Image acquisition. - Cell count in the different layers, corneal nerve count from the basal plexus to the corneal apex
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Keratoconus histological progression - Confocal microscopy (Light scattering)
Description
Histological degradation of the cornea taken at baseline for reference. The confocal microscope allows longitudinal analysis making it possible to carry out comparative qualitative and quantitative analyzes of the corneal tissue during time. In keratoconus, this technique is possible to highlight a reduction in basal plexus nerve density and poorer anterior stromal cell density compared to healthy subjects. Light scattering in vivo, measurement of corneal deformity. Diopter.
Time Frame
Baseline vs Visit at 1 month/6 months/12 months/24 months
Title
Risk factors - Questionnaire
Description
Presence of atopy/allergy Eye rubbing Family medical history Ethnicity Smoking habits Dry eye syndrome
Time Frame
Baseline vs 24 months
Title
Tears proteomics
Description
For 36 participants from Montpellier. Composition and evolution of tears determined by proteomic analysis
Time Frame
Baseline vs Visit at 1 month/6 months
Secondary Outcome Measure Information:
Title
ABCD class worsening between consultations
Description
At baseline and during follow-up
Time Frame
Baseline vs Visit at 1 month/6 months - Baseline vs 12 months - Baseline vs 24 months
Title
Keratoconus histological evolution
Description
Comparison of confocal microscopy results from primary outcomes through time.
Time Frame
Baseline vs Visit at 1 month/6 months
Title
Proteomic profile evolution
Description
Difference between the composition of tears from healthy participants and from keratoconus patients from baseline to short term follow up.
Time Frame
Baseline vs Visit at 1 month/6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants with clinical keratoconus (Rabinowitz criteria with topographic slit lamp abnormalities and visual impairment), preclinical or crude keratoconus (abnormal or suspicious topography with normal slit lamp examination and normal visual acuity, visual acuity) Followed by the ophthalmology services of the CHU Montpellier, CHU Bordeaux or CHU Toulouse For adult Participants: collection of written informed consent, after a period of reflection period For minors: informed consent signed by at least one of the 2 parents or legal representatives legal representatives, and assent of the child after a period of reflection Affiliation to the French social security system or beneficiary of such a system Exclusion Criteria: Person under legal supervision, guardianship or curator History of corneal implant on both eyes Planned relocation before the end of the first stage of treatment (abstention, cross-linking, intra-corneal ring depending on the participant)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vincent DAIEN, PR
Phone
0673055877
Ext
+33
Email
v-daien@chu-montpellier.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vincent DAIEN, PR
Organizational Affiliation
CHU Monptellier
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Gui de Chauliac - Service d'Ophtamologie
City
Montpellier
State/Province
Occitanie
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vincent DAIEN, Pr
Email
v-daien@chu-montpellier.fr
First Name & Middle Initial & Last Name & Degree
Vincent Daien, Pr
First Name & Middle Initial & Last Name & Degree
Fanny Babeau, Dr
First Name & Middle Initial & Last Name & Degree
Pierre Fournié, Pr
First Name & Middle Initial & Last Name & Degree
David Touboul, Pr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Risk Factors and Progression of Keratoconus

We'll reach out to this number within 24 hrs